System may better predict thrombosis in lymphoma

Print Friendly, PDF & Email


Audience at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice
An updated scoring system can more accurately identify lymphoma patients who may require thromboprophylaxis, according to researchers. The revised scoring system, ThroLy, proved more effective than other systems for predicting thromboembolic events in lymphoma patients. Researchers found the updated ThroLy had... [Read Article]
Print Friendly, PDF & Email

Drug approved as part of frontline therapy for HL

Print Friendly, PDF & Email


Brentuximab vedotin
Photo from Business Wire
The Japanese Ministry of Health, Labour and Welfare has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vinblastine, and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma (HL). The approval was based on the phase 3 ECHELON-1 trial. Result from ECHELON-1 were presented at the 2017 ASH... [Read Article]
Print Friendly, PDF & Email

Guidelines for proton therapy in mediastinal lymphomas

Print Friendly, PDF & Email


Treatment room at the
Roberts Proton Therapy
Center at the University
of Pennsylvania.
Photo from Penn Medicine
Proton therapy can help mitigate toxicity in adults with mediastinal lymphomas, but the treatment should only be used in patients expected to derive the most benefit, according to new guidelines from the International Lymphoma Radiation Oncology Group. The... [Read Article]
Print Friendly, PDF & Email

Role of SES in childhood cancer survival disparities

Print Friendly, PDF & Email


Child with cancer
Photo by Bill Branson
Socioeconomic status (SES) may explain some racial/ethnic disparities in childhood cancer survival, according to new research. The study showed that whites had a significant survival advantage over blacks and Hispanics for several childhood cancers. SES significantly mediated the association between race/ethnicity and survival for acute lymphoblastic leukemia (ALL),... [Read Article]
Print Friendly, PDF & Email

Frequent BCCs linked to blood cancers

Print Friendly, PDF & Email


Woman sunbathing
New research suggests people who develop frequent cases of basal cell carcinoma (BCC) have an increased risk of leukemias, lymphomas, and other cancers. “We discovered that people who develop 6 or more basal cell carcinomas during a 10-year period are about 3 times more likely than the general population to develop other, unrelated... [Read Article]
Print Friendly, PDF & Email

Adult CCSs report financial hardships

Print Friendly, PDF & Email


I-Chan Huang, PhD
Photo from St. Jude
Children’s Research
Hospital/Peter Barta
Health-related financial hardship is common among adult survivors of childhood cancer, according to a study published in the Journal of the National Cancer Institute. Researchers analyzed more than 2800 long-term childhood cancer survivors (CCSs) and found that 65% had financial challenges related to their... [Read Article]
Print Friendly, PDF & Email

FDA approves biosimilar filgrastim

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). Nivestym is approved to treat patients with nonmyeloid malignancies who are receiving myelosuppressive chemotherapy or undergoing bone marrow transplant, acute myeloid leukemia patients receiving induction or consolidation chemotherapy,... [Read Article]
Print Friendly, PDF & Email

Interim PET scans identify HL patients with better outcomes

Print Friendly, PDF & Email


Micrograph showing Hodgkin lymphoma
Interim PET scans can identify a subset of Hodgkin lymphoma (HL) patients with a better outcome suitable for de-escalation treatment after upfront BEACOPP without impairing disease control, according to final results of the AHL2011-LYSA study. BEACOPP, compared to ABVD, improves progression-free survival (PFS) but not overall survival (OS) and is associated... [Read Article]
Print Friendly, PDF & Email

Umbralisib has ‘distinct’ safety profile

Print Friendly, PDF & Email


Micrograph showing CLL
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell malignancies. Researchers said the safety profile of umbralisib “was distinct from that of other PI3Kδ inhibitors,” as it produced few immune-mediated adverse events (AEs). Umbralisib also produced an objective response... [Read Article]
Print Friendly, PDF & Email